Gertjan Wolbink

Best Publications

• Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci

  Eli A Stahl;Soumya Raychaudhuri;Soumya Raychaudhuri;Elaine F Remmers;Gang Xie

  1563
  Citations

• Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis

  Geertje M Bartelds;Carla A Wijbrandts;Michael T Nurmohamed;Steven Stapel

  747
  Citations

• Common variants at CD40 and other loci confer risk of rheumatoid arthritis

  Soumya Raychaudhuri;Soumya Raychaudhuri;Soumya Raychaudhuri;Elaine F Remmers;Annette T Lee;Rachel Hackett

  645
  Citations

• Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis

  Gerrit Jan Wolbink;Marijn Vis;Willem Lems;Alexandre E. Voskuyl

  636
  Citations

• Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study.

  J Pijpe;van Gustaaf Imhoff;Frederik Spijkervet;Jan Roodenburg

  611
  Citations

• C-Reactive Protein Colocalizes With Complement in Human Hearts During Acute Myocardial Infarction

  W.K. Lagrand;H.W.M. Niessen;G.J. Wolbink;L.H. Jaspars

  579
  Citations

• Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis.

  Pauline A. van Schouwenburg;Theo Rispens;Gerrit Jan Wolbink

  519
  Citations

• Genetic variants at CD28, PRDM1, and CD2/CD58 are associated with rheumatoid arthritis risk

  Soumya Raychaudhuri;Soumya Raychaudhuri;Soumya Raychaudhuri;Brian P Thomson;Elaine F Remmers;Stephen Eyre

  414
  Citations

• Afucosylated IgG characterizes enveloped viral responses and correlates with COVID-19 severity.

  Mads Delbo Larsen;Erik L. de Graaf;Myrthe E. Sonneveld;H. Rosina Plomp

  384
  Citations

• Arthritis development in patients with arthralgia is strongly associated with anti-citrullinated protein antibody status: a prospective cohort study

  W H Bos;G J Wolbink;M Boers;G J Tijhuis

  348
  Citations

• CRP-MEDIATED ACTIVATION OF COMPLEMENT IN VIVO : ASSESSMENT BY MEASURING CIRCULATING COMPLEMENT-C-REACTIVE PROTEIN COMPLEXES

  G. J. Wolbink;M. C. Brouwer;S. Buysmann;I. J. M. Ten Berge

  317
  Citations

• Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study

  Geertje M Bartelds;Carla A Wijbrandts;Michael T Nurmohamed;Steven O Stapel

  306
  Citations

• Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease.

  R. L. West;Z. Zelinkova;G. J. Wolbink;E. J. Kuipers

  288
  Citations

• Development of the anti–citrullinated protein antibody repertoire prior to the onset of rheumatoid arthritis

  Lotte A. van de Stadt;Margret H. M. T. de Koning;Rob J. van de Stadt;Gertjan Wolbink

  285
  Citations

• Dealing with immunogenicity of biologicals: assessment and clinical relevance

  Gerrit J Wolbink;Lucien A Aarden;B A C Dijkmans

  274
  Citations

• Key findings towards optimising adalimumab treatment: the concentration–effect curve

  Mieke F Pouw;Charlotte L Krieckaert;Michael T Nurmohamed;Desiree van der Kleij

  261
  Citations

• Immunogenicity of anti-tumor necrosis factor antibodies—toward improved methods of anti-antibody measurement

  Lucien Aarden;Sigrid R Ruuls;Gertjan Wolbink

  260
  Citations

• A role for secretory phospholipase A2 and C-reactive protein in the removal of injured cells

  C.Erik Hack;Gert-Jan Wolbink;Caspar Schalkwijk;Han Speijer

  252
  Citations

• Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis

  C J van der Laken;A E Voskuyl;J C Roos;M Stigter van Walsum

  251
  Citations

• The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept

  Anna Jamnitski;Geertje M Bartelds;Michael T Nurmohamed;Pauline A van Schouwenburg

  250
  Citations